Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box and WD repeat domain-containing protein 5 (FBXW5) is a member of the F-box protein family and acts as a substrate recognition module within the SCF (SKP1–CUL1–F-box protein) E3 ubiquitin ligase complex. FBXW5 specifically contains both an F-box motif and WD40 repeats, which enable its binding specificity for certain substrates such as SASS6, SEC23B, TSC2, and LATS1, leading to their ubiquitination and subsequent proteasomal degradation. Through these activities, FBXW5 is involved in the regulation of the cell cycle (e.g., preventing centriole reduplication), autophagy, and key signaling pathways such as the Hippo pathway, impacting cell proliferation, migration, apoptosis, and tumorigenesis. FBXW5 is considered a potential therapeutic target—particularly in oncology—due to its roles in cancer cell proliferation, metastasis, and drug resistance. No direct targeting agents or inhibitors are currently in clinical use.
Not applicable (as there are currently no known drugs acting directly on FBXW5; mechanistically, inhibition or modulation would likely impact ubiquitination of substrates such as LATS1, SASS6, TSC2, SEC23B)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box and WD repeat domain-containing protein 5 (FBXW5).